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Summary
Purpose:  To  determine  the  population-based  seroprevalence  of  varicella  zoster  virus
(VZV)  and  related  risk  factors  in  Izmir.
Materials  and  methods:  A  population-based  household  survey  was  conducted.  A
representative  sample  of  the  population  older  than  15  years  of  age  was  selected
using  multistage  random  sampling.  A  total  of  2136  healthy  persons  participated  in
this  cross-sectional  study.  The  participants  completed  a  questionnaire  designed  to
collect  data  related  to  socio-demographic  characteristics  and  risk  factors.  Blood
samples  were  collected,  and  VZV-speciﬁc  IgG  was  measured  using  an  ELISA.
Results:  In  total,  94.3%  of  individuals  were  seropositive  for  VZV.  The  difference
between  VZV  seroprevalence  in  urban  and  rural  populations  was  signiﬁcant  (OR:
2.6  (95%  CI,  1.7—3.8)).  No  statistically  signiﬁcant  differences  in  seropositivity  were
observed  with  respect  to  other  sociodemographic  characteristics.
Conclusion:  A  large  proportion  of  the  participants  were  found  to  be  immune  to  VZV.
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ttp://dx.doi.org/10.1016/j.jiph.2012.10.003ntroductionaricella  virus  infection  (chicken  pox)  is  an  acute,
ighly contagious  viral  disease  with  a world-
ide distribution.  Varicella-zoster  virus  (VZV),  the
ausative agent,  shows  little  genetic  variation
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and  has  no  animal  reservoir  [1].  In  healthy  chil-
dren, chicken  pox  is  a  self-limiting  disease  with  a
benign course,  but  severe  disease  may  be  encoun-
tered  in  adult  cases  with  immune  deﬁciencies
[2]. Complications  due  to  chicken  pox  are  more
common  in  adults,  and  the  frequency  of  pneu-
monia is  increased  25-fold  in  the  adult  group
[3—5]. There  is  little  information  from  developing
countries on  the  disease  burden  of  varicella-zoster
infection. Most  developing  countries  have  other
vaccine-preventable  diseases  that  cause  signiﬁ-
cantly  greater  morbidity  and  mortality,  and  the
varicella  vaccine  is  not  a  high  priority  for  routine
introduction into  their  national  immunization  pro-
grams [6].
The epidemiology  of  chicken  pox  shows  varia-
tions in  tropical  and  mild  climates.  In  mild  climates,
chicken  pox  is  generally  encountered  during  child-
hood, whereas  its  frequency  increases  in  young
adults  in  tropical  regions  [7,8].
The  chicken  pox  vaccine  generates  long-term
immunity, and  the  disease  occurrence  has  been
reported  to  decrease  by  90%  after  vaccination.
If infection  develops,  its  progression  is  mild,  and
the hospitalization  rate  and  complications  have
been reported  to  decrease  following  chicken  pox
vaccination  [9,10].  Therefore,  determining  the
VZV seroprevalence  and  taking  preventive  meas-
ures for  susceptible  individuals  are  important.  This
population-based  study  aimed  to  describe  the  sero-
prevalence  of  VZV  in  Izmir.
Materials and methods
Survey design
This  cross-sectional  population-based  study
included the  city  population  of  Izmir  (3,739,353).
Izmir is a  city  with  intense  migration  and  is  com-
posed of  individuals  from  different  socioeconomic
backgrounds and  cultures.  The  majority  of  the
population  lives  in  urban  areas.  The  required
responding sample  size  was  calculated  using  the
EpiInfo computer  program  (Centers  for  Disease
Control and  Prevention,  Atlanta,  GA),  and  a
stratiﬁed  sampling  method  was  used.  The  number
of participants  in  this  study  was  deﬁned  with
respect to  the  population  of  each  district.  The
previously deﬁned  seropositivity  of  Izmir  (71.5%)
was accepted  as  the  prevalence  in  the  sample  size
calculation.  The  sample  size  was  calculated  using  a
99% CI  as  1847  participants.  The  list  of  people  to  be
interviewed  was  provided  by  the  Izmir  Provincial
Directorate of  Health.  If  any  of  the  listed  people
could not  be  reached  or  they  declined  participation
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n  the  study,  substitutes  were  identiﬁed  in  the
ame manner  by  randomized  sampling.  During  the
tudy period,  a total  of  2136  healthy  individuals
ged 15  years  or  older  from  29  districts  of  Izmir
ere contacted  between  December  2009  and
arch 2010.
Persons  were  interviewed  face  to  face  and  given
 questionnaire  regarding  their  sociodemographic
haracteristics  (age,  gender,  place  of  residence,
ducation level,  family  size  and  socioeconomic
evel).
The study  protocol  was  approved  by  the  Ethics
ommittee of  the  Provincial  Directorate  of  Health
f Izmir.  Participants  were  informed  about  the
bjective  of  the  study,  and  the  written  consent  of
he voluntary  participants  was  obtained.
erology
n  8  cm3 blood  sample  was  collected  from  each
articipant using  a Vacuette® Standard  tube  holder
Becton Dickinson,  Heidelberg,  Germany).  All  blood
amples were  centrifuged,  and  the  serum  was
tored at  −20 ◦C  until  it  was  tested.  After  all  serum
amples  were  collected,  the  presence  of  anti-VZV
gG was  determined  using  an  ELISA  (DiaSorin,  Italy).
tatistical analysis
ata  were  assessed  using  Statistical  Package  for
ocial Sciences  (SPSS)  version  14.0.  The  Chi  square
est and  percentages  were  used  for  data  analy-
is, and  a  logistic  regression  was  performed  to
etermine  the  risk  factors  for  VZV.  The  level  of
igniﬁcance  was  accepted  as  p <  0.05.
esults
f  the  participants,  38.2%  were  male.  The  sociode-
ographic  characteristics  and  seropositivity  of  the
articipants  are  shown  in  Table  1.
The  prevalence  of  anti-VZV  IgG  positivity  was
4.3%; 95.2%  of  males  and  93.8%  of  females  were
eropositive.  The  age-speciﬁc  VZV  IgG  antibody
eroprevalence rates  are  shown  in  Table  1.  The
eropositivity  rates  ranged  from  93.3%  in  partici-
ants  aged  15—19  years  to  94.4%  in  those  40  years
f age  and  older.  A  signiﬁcant  percentage  of  women
f childbearing  age  were  immune  to  VZV  (93.1%).
A multiple  logistic  regression  analysis  was  con-
ucted.  There  was  no  statistically  signiﬁcant
ifference in  seropositivity  by  age  group,  personal
ncome  level,  education  level,  occupation  or  mari-
al status.  The  seropositivity  rates  of  the  individuals
n urban  and  rural  areas  were  96.1%  and  90.8%,
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Table  1  Demographic  features  and  seropositivity  distributions.
Total  Seropositive
N  %  N  %
Gender
Male 806 38.2  767 95.2
Female 1304 61.8  1223 93.8
Age  groups
15—19  years  135  6.5  126  93.3
20—29  years  340  16.3  321  94.4
30—39  years  427  20.5  401  93.9
40+  years  1180  56.7  1114  94.4
Education
Illiterate  236  11.3  223  94.5
Primary  school  921  43.9  867  94.1
Secondary  school  220  10.5  211  95.9
High  school  425  20.3  397  93.4
University  294  14.0  278  94.6
Occupation
Housewife  865  41.7  810  93.6
Retired  353  17.1  340  96.3
Student  121  5.8  112  92.6
Public  employee  105  5.1  98  93.3
Worker  190  9.2  180  94.7
Other  438  21.1  413  94.3
Monthly  income  TL
<1000  1280  64.1  1211  94.6
1000—2000  517  25.9  482  93.2
>2000  201  10.0  193  96.0
Marital  status
Married 1610 77.1  1519  94.3
Single 385  18.4  358  93.0
Separated/divorced 94 4.5  92  97.9
Living  area
Rural 706 33.4  641  90.8
Urban 1406 66.6  1351  96.1
Household  size
1—4  individuals  632 78.4  1537 94.2
5—9  individuals  430 20.7  406 94.4
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espectively.  This  difference  was  statistically  sig-
iﬁcant (OR:  2.6  (95%  CI,  1.7—3.8)).
iscussion
he  total  VZV  seroprevalence  in  this  study  was
4.3%.  Kanra  et  al.  reported  a  chicken  pox  preva-
ence  of  77.8%  in  their  study,  which  was  conducted
n subjects  younger  than  30  years  of  age  in  a  total  of
 cities  in  2001  [11].  Another  study  identiﬁed  71.5%
eropositivity  in  590  persons  in  Izmir  in  2008  [12].
n a  study  performed  in  Northern  Cyprus,  84.1%  of
ubjects  younger  than  30  years  of  age  were  seropos-
tive  [13].  In  Erzurum,  the  VZV  seroprevalence  was
8% in  subjects  younger  than  30  years  of  age  [14].
s
b
f0.9  19  100.0
In  this  study,  93.3%  of  the  15-  to  19-year-old  age
roup was  seropositive.  In  a previous  study,  VZV
ositivity  was  detected  in  61.6%  of  7-  to  15-year-
ld children  who  attended  schools  in  the  center  of
anisa [15].  Dilli  et  al.  reported  a  VZV  seroposi-
ivity in  adolescents  in  Ankara  of  55.7%  [16],  while
he seroprevalence  of  VZV  was  reported  to  be  78%
n primary  school  students  in  the  city  of  Adana
17]. However,  a higher  rate  of  seropositivity  was
etected  in  our  study  compared  to  the  other  stud-
es. These  differences  could  be  attributable  to  the
ifferent  climates  and  cultural  practices  in  the
tudied  regions.
In Western  countries,  the  seroprevalence  has
een reported  to  increase  with  age  [18].  Dif-
erent results  have  been  reported  in  different
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geographical  regions.  The  seroprevalence  was  39%
in children  younger  than  14  years  in  Athens  [19],
while the  seroprevalence  of  VZV  was  reported  to  be
80.6% in  the  United  Arab  Emirates  [20].  Likewise,
the seroprevalence  was  94.6%  among  young  adults
in Israel  [21],  80%  in  Bolivia  [22],  and  68.2%  in  India
[23].
Kanra et  al.  reported  no  statistically  signiﬁ-
cant difference  in  the  VZV  seroprevalence  between
subjects  living  in  urban  and  suburban  areas  [11].
Similar results  have  been  emphasized  in  previous
studies performed  in  Izmir  [12].  However,  there  was
a statistically  signiﬁcant  difference  between  rural
and urban  regions  in  this  study.  Lolekha  reported
that the  seroprevalence  was  signiﬁcantly  higher  in
the urban  population  than  in  the  rural  population,
and they  hypothesized  that  this  was  due  to  popula-
tion density  [24].
There  were  some  limitations  to  our  study.  The
data collected  via  questionnaire  were  dependent
on the  study  subjects’  answers.  This  population-
based study  was  performed  using  a  random
sampling method,  and  the  results  therefore  repre-
sent the  entire  Izmir  population.  We  did  not  record
past history  of  chickenpox.  Other  rash-causing  dis-
eases are  often  confused  with  chicken  pox,  and  a
negative history  of  varicella  is  not  a  reliable  pre-
dictor  of  varicella  seropositivity  [11,25].
Determining  VZV  seroprevalence  is  important  for
identifying  susceptible  individuals  and  taking  pre-
ventive precautions.  Cohen  stated  that  knowledge
of pre-vaccination  seroepidemiology  is  important
for evaluating  the  effect  of  vaccination  programs
on the  epidemiology  of  the  disease  [21].  In  devel-
oped  countries,  it  has  been  emphasized  that  the
cost-effectiveness  of  the  vaccine  should  be  eval-
uated  prior  to  including  the  chicken  pox  vaccine
into the  routine  vaccination  schedule  [26].  How-
ever, there  are  obstacles  (e.g.,  accessibility,  cost  of
the vaccine)  to  vaccination  in  many  countries  [27].
Chicken  pox  was  not  a  notiﬁable  disease  in
Turkey until  2011.  The  Turkish  Ministry  of  Health
and the  National  Immunization  Advisory  Committee
introduced  varicella  vaccination  into  the  national
routine  immunization  program,  and  it  will  be
included  starting  in  2014.  According  to  the  decision
of the  Ministry  of  Health,  the  chicken  pox  vaccine
will  be  administered  in  the  12th  month  of  life  in  a
single dose.
The routine  use  of  the  varicella  vaccine  is
controversial. Some  authors,  particularly  pediatri-
cians,  have  stated  that  the  VZV  vaccine  should
be introduced  into  the  routine  childhood  vacci-
nation  program  in  Turkey  [11,12,14]. Additionally,
Dinleyici et  al.  indicated  that  hospitalization  as  a
result of  varicella  infection  is  not  uncommon  inS.  Kose  et  al.
hildren,  and  universal  vaccination  is  the  only  real-
stic option  for  preventing  severe  complications  and
eath [28].  However,  some  public  health  special-
sts raise  different  concerns,  believing  that  it  is  not
ppropriate  to  routinely  include  the  varicella  vac-
ine in  the  childhood  vaccination  program  in  Turkey.
or example,  Ergin  and  Durusoy  reported  that  this
accine did  not  generate  life-long  immunity,  requir-
ng a booster  dose  and  a zoster  vaccination  at
ater ages.  The  current  cost-effectiveness  studies
o not  consider  these  additional  doses,  and  new
ost-effectiveness  analyses  are  required  [29].
This study  contributes  valuable  information
egarding the  current  status  of  VZV  seroprevalence
rior to  introducing  the  varicella  vaccine  into  the
outine  vaccination  program.  Further  studies  will
e required  after  introducing  the  varicella  vaccine
nto the  routine  vaccination  program  to  evaluate
accination coverage  and  its  effectiveness.
In  conclusion,  all  age  groups  had  a  high  seropos-
tivity rate  in  Izmir.  Although  Izmir  does  not  have
 cold  climate  for  much  of  the  year,  a  large  pro-
ortion  of  the  population  was  naturally  immunized
gainst VZV.
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